0001193125-26-212001
SEC filingRevenue surged 810% to $2.8M on milestone recognition via input method as costs incurred, but operating loss widened 40% to -$26.9M from R&D acceleration, driving net loss of -$23.0M and cash burn of -$23.1M amid ongoing clinical investments.
Aligos Therapeutics reported Q1 FY2026 results reflecting revenue growth from contractual milestones alongside escalating R&D investments in its clinical pipeline. Revenue reached $2.8 million, up 810% from $311 thousand in the prior-year quarter. This increase stems from the input method of revenue recognition over time as costs are incurred on customer contracts, enabling steady milestone capture amid ongoing development activities.
Net income swung to a -$23.0 million loss from a $43.1 million profit, reflecting a -153.5% change. Beyond operating losses, this shift was principally due to fluctuations in the fair value of 2023 Common Warrants, remeasured quarterly via the Black-Scholes model and sensitive to stock price changes between periods. Diluted EPS followed suit at -$2.21, down 4.7% from -$2.11, as per-share losses compounded from pipeline acceleration.